Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 28

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
31, 2025 
     16,034,444  
    $160,344  
    $67,611,000  
    $(64,971,613) 
    $2,799,731 
  
    Balance 
     16,034,444  
    $160,344  
    $67,611,000  
    $(64,971,613) 
    $2,799,731 

See accompanying notes to the unaudited condensed consolidated
financial statements

F-3

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Cash
Flows

    2025  
    2024 

    For the three months ended March 31, 

    2025  
    2024 
  
    Cash flows from operating activities: 

    Net loss 
    $(4,532,430) 
    $(3,806,677)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     -  
     735 
  
    Stock-based compensation 
     240,891  
     774,691 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current and non-current assets 
     7,346  
     332,125 
  
    Accounts payable and other current liabilities 
     (762,338) 
     (1,237,499)
  
    Operating lease right-of-use asset and liability, net 
     (596) 
     163 
  
    Net cash used in operating activities 
     (5,047,127) 
     (3,936,462)

    Cash flows from financing activities: 

    Proceeds from issuance of shares of common stock and warrants 
     3,482,650  
     336,044 
  
    Issuance costs 
     (331,255) 
     (19,997)
  
    Net cash provided by financing activities 
     3,151,395  
     316,047 

    Net decrease in cash and cash equivalents 
     (1,895,732) 
     (3,620,415)

    Cash and cash equivalents at beginning of period 
     5,786,753  
     13,362,053 

    Cash and cash